The research team: "Until now, CRISPR wasn't used for cancer because it was assumed that knocking out a single gene wouldn't topple the whole structure. We demonstrate that some genes are absolutely ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Crispr Therapeutics AG's current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles, making future pipeline progress critical. Management is focused on improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results